Global Congestive Heart Disease Marker Testing Market
Congestive heart disease tests are diagnostic tests for the disease. Cardiac biomarker testing is helpful for immediate diagnosis and treatment. Cardiac biomarkers evaluate the cardiac function and help in identifying the severity and complexity of procedures to treat CVD. The primary indications for the CVD are acute coronary syndrome (ACS) that include congestive heart failure (CHF), angina pectoris (AP) peripheral arterial disease (PAD), acute myocardial infarction (AMI) and others. The causes for CVD are include tuxedo, high blood pressure, diabetes, inadequate exercise, stress, unhealthy diet, obesity, high blood cholesterol, and alcoholism.
Increase in geriatric population, rise in funding from private-public Organizations for cardiac biomarkers research, and ongoing research and clinical trials for identification of the newer cardiac biomarkers are the key factors boost the congestive heart disease marker testing market over the forecast period. Moreover, the global congestive heart disease marker tests, and increase the cost of diagnosing and evaluating cardiovascular disease market over the forecast period. However, factors technical problems such as sample collection and storage, stringent regulatory guidelines,
A sample of this report is available upon request @
The congestive heart disease marker test is segmented on the basis of product type, test type, application, and end-user
Based on product type, the congestive heart disease has been segmented into the following:
- Reagents
- Kits
- Instruments
- Chemiluminescence
- Immunofluorescence
- ELISA
- immunochromatography
Based on test type, the congestive heart disease has been segmented into the following:
- Myocardial muscle creatine kinase (CK-MB)
- myoglobin
- Troponins (T and I)
- Ischemia Modified Albumin (IMA)
- NT-proBNP or Brain Natriuretic Peptide (BNP) or
- Others
Based on application, the congestive heart disease has been segmented into the following:
- Myocardial infarction
- Acute Coronary Syndrome
- Congestive Heart Failure
- Atherosclerosis
- Others
Based on the end-user, the congestive heart disease test has been segmented into the following:
- Hospitals
- Clinics
- Diagnostic Centers
- Others
To view TOC of this report is available upon request @
In the congestive heart disease marker test market. For instance, in June 2011, Thermo Fisher Scientific announced that it would like to see its Thermo Scientific BRAHMS biomarker assays on Alere’s leading point-of-care triage platform.
Need more information about this report @
Geographically, the congestive heart disease has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the dominant share owing to increase in the prevalence of congestive heart failures (AHA), and nearly 550,000 new cases are diagnosed each year in the United States). The increasing number of patients suffering from cardiovascular disorders is estimated to be increasing. Europe holds a major share in the global congestive heart disease marker tests market attributed to increase in the prevalence of congestive heart failure (BHF) approximately 7 Mn people are suffering from the various cardiovascular disease in UK). Rise in the incidence of congestive heart disease in the UK (approximately 4000 cases per year in newborn babies), increase in the research and development, and novel congestive heart disease biomarker tests might fuel the growth of the market. The Asia-Pacific is expected to increase its exposure to the prevalence of myocardial infarction, public-private initiatives to increase the awareness of early cardiac disease diagnosis in physicians and patients.
F. Hoffmann-La Roche (Switzerland), Siemens AG (Germany), Abbott Laboratories (US), Danaher Corporation (US), Nanogen, Inc. (US), bioMérieux SA (France), Alere, Inc. (US), LSI Medience Corporation (Mitsubishi Chemical Holdings Corporation, Japan), Randox Laboratories Ltd (UK), Ortho Clinical Diagnostics (The Carlyle Group) (US), and Guangzhou Wondfo Biotech Co. Ltd. , (China) to name a few.
Get access to full summary @
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firms, which follows a holistic approach to solve the needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and making better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help you make keys to business growth. Precision Business Insights is the most valuable partner in the world
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): 1-866-598-1553